Four open-label, randomized trials evaluated gefitinib vs docetaxel in patients with pre-treated advanced NSCLC: (Lancet 2008; 372: 1809), (J Clin Oncol 2008; 26: 4244), (J Clin Oncol 2008; 26: Abs 8025), (Cufer et al., Anticancer Drugs 2006; 17: 401). In this meta-analysis results were consistent with those of the individual studies. Given the similar/superior efficacy demonstrated by gefitinib, its favorable tolerability profile, quality of life benefits and oral administration, gefitinib was found to have a favorable benefit-risk profile compared with docetaxel.
COBISS.SI-ID: 27246809
In small-cell lung cancer (SCLC), resistance to cancer drugs presents a major problem, limiting the effectiveness of chemotherapy. In a systematic review of studies evaluating the predictive value of multidrug resistance-associated proteins (MDR1, MRP1, MRP2 and MVP), topoisomerase II and ERCC1 for chemotherapy outcomes is presented. The authors conclude that a better understanding of the biology of SCLC is of utmost importance to enable personalized therapy and to improve survival rates in this, so far, poorly controlled disease.